MBI Group announced on Friday that it has completed a project to construct and renovate patient care spaces at The Mount Sinai Hospital's Guggenheim Pavilion, located at 1190 Fifth Avenue on Manhattan's Upper East Side.
The company added that it was selected under a competitive bid process .
Under the four-month project, MBI was responsible for the renovation of patient spaces in the haematology, oncology and bone marrow transplant unit. The renovations of patient rooms, nursing stations, restrooms and corridors included interior demolition, millwork, drywall, ceiling work, tiling, terrazzo, flooring, painting, toilet installation, wall protection, plumbing and HVAC, as well as electrical work.
Founded in 1852, The Mount Sinai Hospital is one of the oldest and largest teaching hospitals in the US. The integrated health care system provides exceptional medical care to local and global communities. It is internationally acclaimed for its excellence in research, patient care, and education across a range of specialties.
Established in 1987, MBI Group is a full-service construction firm providing interior fit-outs and core and shell construction for corporate, educational, healthcare, hospitality, institutional, mixed-use and retail facilities.
GE HealthCare's Photonova Spectra gains FDA clearance
HUTCHMED launches Phase III trial of HMPL-760 for DLBCL in China
GSK secures Japan Orphan Drug status for lung cancer ADC
TheraCryf advances lead addiction programme to final preclinical stage
Dizal meets primary endpoint in Phase 3 study of ZEGFROVY (sunvozertinib) monotherapy
Novartis to acquire PI3K-alpha inhibitor program from Synnovation in deal worth up to USD3bn
IBA and Telix partner to expand US radiopharmaceutical manufacturing capacity
Pfizer reports Phase 3 TALAPRO-3 results showing improved outcomes in metastatic prostate cancer
Mabtech partners with Sai Life Sciences to expand access to EYRA multiplex immunology platform
Samsung Bioepis partners with Sandoz on up to five next-generation biosimilars
Avacta opens Phase 1 trial for AVA6103 cancer therapy in US
Imfinzi approved in EU for perioperative treatment of early gastric and gastroesophageal cancers
Aditxt acquires Ignite Proteomics to enhance cancer therapy selection
NASA awards Redwire USD4m to advance drug development in microgravity
Elicera Therapeutics receives Japanese patent allowance for ELC-401 CAR T-cell candidate